Peptide Synthesis Market to Hit USD 1.41 Billion by 2029 with 11.7% CAGR
"Thermo Fisher Scientific Inc. is one of the dominant players in the peptide synthesis market. The company's leading position is attributable to its diversified product portfolio, strong geographic presence, and adoption of various growth strategies."
The market for peptide synthesis market is competitive, with key players strategizing to capture the majority market share. Prominent players in the peptide synthesis market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies Inc. (US), Kaneka Corporation (Japan), GenScript (China)
The Peptide Synthesis market valued at US$ 0.78 Billion in 2023, is forecasted to grow at a robust CAGR of 11.7%, reaching US$ 0.81 Billion in 2024 and an impressive US$ 1.41 Billion by 2029. The peptide synthesis market is driven by the growing demand for therapeutic peptides in treating chronic diseases, including cancer, diabetes, and cardiovascular disorders. Advancements in solid-phase peptide synthesis (SPPS) and hybrid approaches have significantly improved efficiency, yield, and cost-effectiveness, fueling adoption in pharmaceutical R&D. The rise of personalized medicine has further expanded the need for custom peptide synthesis, supporting applications in targeted therapies and biomarker research. Emerging trends such as the integration of automation and AI-driven platforms among the instruments is further likely to fuel the market growth in coming years.
Browse in-depth TOC on " Peptide Synthesis Market"
513 - Tables
55 - Figures
460 - Pages
Based on offerings, the market is segmented into products and services. By-products market is further divided into consumables and instruments. Among these consumables dominated the peptide synthesis market. The consumables segment is further bifurcated into reagents and other consumables. The reagents market is further divided into resins, amino acids, coupling reagents, dyes & fluorescent labeling reagents, deprotection agents, cleavage reagents, and other reagents. In 2023, the resins segment accounted for the largest share of the peptide synthesis market. Resins play an important role in solid-phase peptide synthesis (SPPS), the most widely used method for peptide production. For instance, polystyrene-based and PEG-based resins are extensively used due to their high stability and scalability.
The instruments segment is further divided into peptide synthesizers, chromatography equipment, lyophilizers, and others. The peptide synthesizer segment is further divided into automated and manual peptide synthesizers. Peptide synthesizers dominated the instruments market due to their ability to automate and streamline peptide production, making them essential for research and industrial applications. The growing demand for custom peptides in drug discovery, diagnostic research, and therapeutic applications has further boosted the adoption of advanced synthesizers.
The services segment is further divided into peptide library synthesis, peptide synthesis, peptide purification services, and peptide analysis services. The peptide synthesis segment dominated the services segment. The increasing adoption of peptides in emerging fields such as personalized medicine, vaccine development, and epigenetics drives demand for custom synthesis solutions, fostering growth in the segment.
Based on technique, the peptide synthesis market is segmented into chemical and biological. The chemical segment is further divided into solid-phase peptide synthesis, solution-phase peptide synthesis, and others. The biological segment is divided into recombinant DNA technology and enzymes. The chemical segment dominated the market in 2023. The solid-phase peptide synthesis (SPPS) segment dominates the peptide synthesis market due to its efficiency, scalability, and widespread adoption in research and commercial applications. The dominance of SPPS is further driven by advancements in automation and reagent technologies, which have significantly reduced synthesis time and enhanced yield.
Based on application, the market is divided into therapeutics, diagnostics, and research & development. Therapeutics by indication is further divided into cancer, diabetes, obesity, autoimmune disease, and other disease indications. Therapeutics by molecules is further segmented into peptide-based vaccines, peptide-drug conjugates (PDCs), peptide inhibitors, and other molecules. Therapeutic applications dominated the peptide synthesis market due to the growing demand for peptide-based drugs, which offer targeted and effective treatments with fewer side effects compared to traditional small molecules.
The peptide synthesis market is segmented by end users into pharmaceutical and biotechnology companies, CDMOS & CROS, academic and research institutes, medical device companies, and hospitals and diagnostic centers. The pharmaceutical and biotechnology companies segment held the largest market share in 2023. The rise of peptide-based drugs and biologics has led to increased investments by pharmaceutical and biotech firms in peptide synthesis technologies, particularly in the production of therapeutic peptides for diseases such as cancer, diabetes, and autoimmune disorders. These factors are fueling the growth of the segment.
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America dominated the peptide synthesis market in 2023, and the Asia Pacific region is likely to grow at a significant CAGR during the forecast period. US-dominated North American peptide synthesis market owing to the presence of strong pharmaceutical and biotechnology companies in the country, advanced research infrastructure, and significant investments in drug discovery and development. The Asia Pacific region is anticipated to grow at a significant CAGR due to growing focus on personalized medicine and peptide-based therapeutics in the region fuels the demand for advanced peptide synthesis technologies.
The market for peptide synthesis market is competitive, with key players strategizing to capture the majority market share. Prominent players in the peptide synthesis market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies Inc. (US), Kaneka Corporation (Japan), GenScript (China), and Bachem Holding AG (Switzerland), among others. The market players have adopted various organic and inorganic growth strategies, such as the development of advanced products, partnerships, agreements, expansions, and acquisitions to strengthen their position in the peptide synthesis market.
Thermo Fisher Scientific Inc. is one of the dominant players in the peptide synthesis market. The company's leading position is attributable to its diversified product portfolio, strong geographic presence, and adoption of various growth strategies. The company offers a wide range of peptide synthesis products and services. The company has adopted different growth strategies, such as deals that include agreements, and acquisitions, to maintain its leading position in the peptide synthesis market. The company's strong customer support and extensive distribution network further solidify the company's leadership position in the market.
Merck KGaA is a key player in the peptide synthesis market, leveraging its expertise in life sciences and advanced chemical technologies. The company's Novabiochem product line offers a broad range of high-quality reagents, resins, and building blocks essential for efficient and reliable peptide synthesis. Merck KGaA focuses on innovation supporting advanced techniques such as microwave-assisted synthesis, which significantly improves reaction efficiency and yield. The company's strategic partnerships and increased investments in biopharmaceutical R&D further enhance its competitive edge in the market. Merck's strong geographic presence and adoption of growth strategies further contribute to its dominance in the market.
For more information, Inquire Now!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
6 hours ago
- Globe and Mail
Blood Cell Factors Market Expected to Touch USD 4.31 Bn by 2032, CAGR of 3.6% Detailed in New Report
The global blood cell factors market growth is driven by the increasing prevalence of blood disorders, advancements in healthcare infrastructure, and rising demand for effective treatments. Additionally, growing awareness about blood cell factors and their role in treating various blood-related conditions are expected to fuel the market growth. Blood Cell Factors Market Insights The Blood Cell Factors industry is experiencing robust expansion driven by rising hemophilia treatment demand and novel biologics pipelines. This expert analysis explores market size, dynamics, and actionable insights to guide strategic decision-making in 2025–2032. The Global Blood Cell Factors Market size is estimated to be valued at USD 3.37 Bn in 2025 and is expected to reach USD 4.31 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 3.6% from 2025 to 2032. According to the latest Blood Cell Factors market size assessment and Blood Cell Factors market report, global market revenue surpassed USD 3.4 Bn in 2024, indicating an upward shift in market share across major regions. This market forecast underscores expanding industry size and business growth opportunities. Market Key Takeaways: Region: • North America: Strong R&D investments in recombinant factors drive advanced product launches. • Latin America: Rising healthcare infrastructure improvements accelerate treatment adoption. • Europe: Regulatory harmonization fosters cross-border supply chains. • Asia Pacific: Expanding manufacturing capacity and favorable pricing boost volume. • Middle East: Government-backed hemophilia programs underpin demand growth. • Africa: Emerging import channels and NGO support enhance access. Segment Covers: • Product Type: – Recombinant Factors: Example: Amgen's 2024 launch of Factor VIII rAHFV captured 42% of new biologics uptake. – Plasma-Derived Factors: Sanofi's Purified FVIII retains stable pricing leadership in 2025. – Gene Therapy Platforms: Early-stage pipelines by Regeneron target one-dose cures. • Application: – Hemophilia A/B: Eli Lilly's factor IX pegylated formulation grew 28% in 2024 revenues. – Von Willebrand Disease: Pfizer's new multi‐domain VWF therapy gained EMA approval in 2024. • End User: – Hospitals & Clinics: Accounted for 65% of procurement in 2024. – Specialty Centers: Focused infusion protocols drive repeat purchase patterns. Growth Factors: • Rising Prevalence of Coagulation Disorders: The global hemophilia population increased by 4.5% between 2023 and 2024, driving factor consumption. • Strategic Partnerships: In 2024, Roche's collaboration with a biotech startup increased manufacturing capacity by 15% and expanded contract manufacturing revenue by USD 80 Mn. • Blood Cell Factors market share gains hinge on targeted rebates and patient support programs in North America and Europe, lifting volume growth despite pricing pressures. • Increased public funding for rare diseases in Japan and Australia boosted factor adoption by 12% in 2024. Book the Latest Edition of this Market Study Get Up to 25 % Discount: Market Trends: • Personalized Medicine: Tailored dosing algorithms using AI-driven pharmacokinetic models reduced bleed rates by 30% in 2024 trials. • Biosimilar Entrants: Novartis's pipeline biosimilar of FVIII (expected 2025 launch) is projected to undercut reference pricing by 20%. • Digital Adherence Tools: Mobile infusion tracking apps improved on-time dosing by 18% across 2024 real-world studies. • Blood Cell Factors market trends indicate heightened M&A activity—with Teva's acquisition of a plasma facility in 2024 enhancing Asia Pacific supply by 25%. Actionable Insights: • Production Capacity: Global recombinant factor capacity rose to 150 kg in 2024, up 10% YOY, enabling wider supply. • Pricing Benchmarks: Median USD 0.85/IU for FVIII in Western Europe vs. USD 0.65/IU in Asia Pacific illustrates import-driven discounts. • Exports & Imports: Asia Pacific exported USD 220 Mn of plasma-derived factors in 2024, while Africa imported USD 90 Mn, reflecting demand-supply gaps. • Use-Case Volumes: Hospital procurement volumes for prophylactic regimens grew 14% in Latin America in 2024, outpacing on-demand therapy. • Nano-Indicators: Patient registry expansions in the Middle East added 5,000 new documented cases in 2024, informing localized forecasting models. • Blood Cell Factors market revenue analyses highlight cost-per-patient as a leading macro-indicator for future investment. Key Players: • Amgen Inc. • Johnson & Johnson • Roche Holding AG • Novartis AG • Pfizer Inc. • Bristol-Myers Squibb Company • Eli Lilly Company • Gilead Sciences Inc. • Sanofi S.A. • Merck & Co. Inc. • Teva Pharmaceutical Industries Ltd. • AbbVie Inc. • Celgene Corporation • Takeda Pharmaceutical Company Limited • Regeneron Pharmaceuticals Inc. Get Customization on this Report: Competitive Strategies: – Roche's 2024 capacity partnership with Biogen boosted contract revenues by USD 80 Mn and reduced production costs by 12%. – Novartis's biosimilar rollout strategy undercut reference FVIII pricing by 20%, capturing 8% market share in Europe within six months. – Pfizer's bundled care agreements with specialty clinics in North America in 2024 increased annualized purchases by 22%. Frequently Asked Questions 1. Who are the dominant players in the Blood Cell Factors market? Major players include Amgen, Roche, Novartis, Pfizer, and Sanofi, each commanding significant market share through diversified portfolios and strategic alliances. 2. What will be the size of the Blood Cell Factors market in the coming years? The market is forecast to grow from USD 3.37 Bn in 2025 to USD 4.31 Bn by 2032 at a 3.6% CAGR. 3. Which end-user industry has the largest growth opportunity? Hospitals & clinics represent the largest segment, accounting for over 65% of revenues in 2024, driven by prophylactic treatment mandates. 4. How will market development trends evolve over the next five years? Trends include AI-enabled dosing, gene therapy maturation, and biosimilar price competition, reshaping market dynamics and business growth strategies. 5. What is the nature of the competitive landscape and challenges in the Blood Cell Factors market? Intense R&D races, biosimilar threats, and supply-chain complexities define the competitive landscape, while high manufacturing costs remain a key restraint. 6. What go-to-market strategies are commonly adopted in the Blood Cell Factors market? Strategies include co-development partnerships, patient support services, value-based contracts, and digital adherence platforms to drive uptake and retention. About Coherent Market Insights Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
Globe and Mail
6 hours ago
- Globe and Mail
Why Nintendo Stock Surged Today
Nintendo (OTC: NTDOY) stock saw another day of big gains in Wednesday's trading. The company's share price gained 6.1% in the daily session and is now up 56.5% across 2025. Nintendo's gains today were driven by indications that demand for its recently released Switch 2 gaming console remains quite high. The Switch 2 quickly became the fastest-selling gaming platform in history following its release earlier this month, and the new system is powering a strong rally for Nintendo stock. Switch 2 continues to push Nintendo stock higher Nintendo released its Switch 2 platform on June 5, and the new console has gotten off to a fantastic start. The console, which launched at a $449 price point, sold more than 1.1 million units in the U.S. within its first week on store shelves. The performance was good enough to make it the most successful video game platform launch in history. On a worldwide basis, the Switch 2 managed to sell 3.5 million units in just four days -- a performance that also set a new sales record. Now, new shipments from Nintendo mean that retailers are restocking the red-hot console -- and reports suggest that the platform is continuing to quickly sell out. What's next for Nintendo? Nintendo appears to have a big hit on its hands with the Switch 2. Unlike some other console launches, the company did a commendable job ensuring that it had a lot of units produced -- but demand still appears to be significantly exceeding supply at some point. While there is some risk for investors that front-loaded demand for the new console may not provide a great indicator as to the platform's long-term performance outlook, the launch has clearly gone very well. Should you invest $1,000 in Nintendo right now? Before you buy stock in Nintendo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nintendo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $658,297!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $883,386!* Now, it's worth noting Stock Advisor 's total average return is992% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Japan Forward
7 hours ago
- Japan Forward
Ishiba Must Not Allow Prolonged Japan-US Trade Negotiations
このページを 日本語 で読む As Prime Minister Shigeru Ishiba flails and Japanese diplomacy deteriorates, we cannot help but feel disheartened. Ishiba managed to meet with United States President Donald Trump for about 30 minutes in Kananaskis, western Canada, host site of the 2025 Group of Seven Summit. However, their failure to reach an agreement on tariffs on the sidelines of the G7 was disappointing. At the same time, it was hardly unexpected. There is one issue that should not be overlooked but went unmentioned. Didn't the two leaders discuss the Middle East crisis and the fierce ongoing fighting between Israel and Iran? Japan relies on the Middle East for over 90% of its crude oil. Also, many tankers bound for Japan sail through the Persian Gulf. Therefore, the conflict threatens to disrupt oil shipment routes. For Japan, responding to the situation in the Middle East should be a major issue on a par with tariff negotiations. The summit discussions clearly fell short. After all, why would you meet with the president of your ally and not discuss the Middle East? G7 working session on the global economy. (©Canada G7 website) For the Prime Minister not to disclose what was actually discussed would also be strange. Japan could be viewed as sidelined in the Middle East situation. Either way, hasn't the Prime Minister demonstrated a lack of resolve in shouldering responsibility for the nation's destiny? Ishiba did comment on the failure to reach an agreement in the tariff negotiations, however. "We are exploring the possibility of reaching an agreement in line with the national interest," said the Prime Minister. Ishiba is right not to be so eager to achieve results that he makes easy concessions on issues vital to Japan. Poor outcomes on issues such as US tariffs on Japanese automobiles could undermine the national interest. It was already apparent that only the two leaders would be able to break the deadlock in negotiations. Minister of State for Economic Revitalization Ryosei Akazawa has already participated in a total of six Cabinet-level meetings with his US counterparts. However, they failed to reach an agreement. So, why is there no target date for when an agreement will be reached, even after the Ishiba-Trump meeting? There is also concern that the Trump administration's emphasis on negotiations with China may dampen momentum for an agreement with Japan. Initially, the administration said Japan-US negotiations were its top priority. We should not let this situation prolong the Japan-US trade negotiations. Moreover, we cannot allow the negative impact of Trump's tariffs on the Japanese economy to spread. The US administration's high tariff policy approach is fluid. Trump has declared that there may be further increases in tariffs on motor vehicles. However, US Treasury Secretary Scott Bessent has indicated the American side may extend the current reciprocal tariffs suspension. What we need from the Ishiba administration is a strategic and proactive approach to pursuing national interests. It cannot allow Japan to be constantly at the mercy of the US side. Likewise, there is no need to be passive or to think that the outcome of any agreement depends on Trump. Author: Editorial Board, The Sankei Shimbun このページを 日本語 で読む
